CH240099A - Process for the preparation of a lactone of the cyclopentanopolyhydrophenanthrene series. - Google Patents

Process for the preparation of a lactone of the cyclopentanopolyhydrophenanthrene series.

Info

Publication number
CH240099A
CH240099A CH240099DA CH240099A CH 240099 A CH240099 A CH 240099A CH 240099D A CH240099D A CH 240099DA CH 240099 A CH240099 A CH 240099A
Authority
CH
Switzerland
Prior art keywords
sep
lactone
allo
acid
preparation
Prior art date
Application number
Other languages
German (de)
Inventor
Aktiengesellschaft Ciba
Original Assignee
Ciba Geigy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy filed Critical Ciba Geigy
Publication of CH240099A publication Critical patent/CH240099A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J19/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 by a lactone ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J75/00Processes for the preparation of steroids in general

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

  

  Verfahren zur Herstellung eines     Laetons    der     Cyelopentanopolyhydrophenanthren-Reihe.       Gegenstand des vorliegenden Patentes ist  ein Verfahren zur Herstellung eines     Lactons     der     Cyclopentanopolyhydrophenanthren-Reihe,     welches dadurch gekennzeichnet ist, dass man  ein     3,21-Diacyloxy-allo    -     pregnan    - 20 -     on,    das       konfigurativ    dem     Cholestanol    entspricht, mit  einem     Halogenessigsäureester    kondensiert, aus  dem entstandenen Gemisch das     42 ,

  22-3-Acyl-          oxy-21-        oxy-        nor    -     allocholen        -säure    -     lacton    ab  trennt und auf diese Verbindung verseifende       Mittel    einwirken lässt.  



  Die so erhaltene neue     Verbindung,    das       42 @22-3,21-Dioxy-nor-allo    -     cholensäure    -     lacton,     schmilzt bei 248 - 250 . Sie soll therapeu  tische Verwendung finden oder als Zwischen  produkt zur Herstellung therapeutisch ver  wendbarer Verbindungen dienen.  



       Beispiel:     600 mg     3,21-Diacetoxy-allo-pregnan-20-on     vom F. 153 -154 , das     konfigurativ    dem       Cholestanol    entspricht, werden in 5 cm' ab  solutem Benzol gelöst und mit 300 mg Brom  essigester und 120 mg Zink in Reaktion ge-    bracht. Man erwärmt 2 Stunden auf dem  Wasserbade, zersetzt dann mit Eis und ver  dünnter     Salzsäure    und nimmt das Reaktions  produkt     in    Äther auf. Die Ätherlösung wird  mit Wasser und verdünnter     Bicarbonatlösung     ausgewaschen, über wasserfreiem Natrium  sulfat getrocknet und eingedampft.

   Der Rück  stand wird mit 6 g     Aluminiumoxyd    vermischt  und in einem     Sublimationsgefäss    bei 0,01 mm  Druck auf 180  erwärmt, bis auf dem ge  kühlten Kondensationsgefäss sich kein Destil  lat mehr niederschlägt. Das Destillat wird in       benzolischer    Lösung an     Aluminiumoxyd    ad  sorbiert und durch fraktionierte     Elution    mit  Benzol, Äther und Aceton     in    eine Anzahl  von Fraktionen zerlegt. Die verschiedenen  Fraktionen werden im     Legaltest    geprüft und  diejenigen, die' eine positive Farbreaktion  geben, von den übrigen getrennt.

   Durch frak  tionierte Kristallisation aus     Essigester-Hexan     können die     einzelnen    Anteile gereinigt werden.  



  -Aus den Fraktionen mit positivem Legal  test gewinnt man in der Hauptsache das       .410,11-3_Acetoxy-21-oxy-nor    - allo-cholen-säure-    
EMI0002.0001     
  
    lacton <SEP> vom <SEP> F. <SEP> 193 <SEP> -194 , <SEP> das <SEP> durch <SEP> saure
<tb>  Verseifung <SEP> in <SEP> das <SEP> cj211>22-3,21-D1oS.'-llol'-allo  cholensäure-lacton <SEP> vom <SEP> F. <SEP> 248-250  <SEP> umge  wandelt <SEP> wird.



  Process for the preparation of a laeton of the cyelopentanopolyhydrophenanthrene series. The subject of the present patent is a process for the production of a lactone of the cyclopentanopolyhydrophenanthrene series, which is characterized in that a 3,21-diacyloxy-allo-pregnan-20-one, which corresponds configuratively to cholestanol, is condensed with a haloacetic acid ester the resulting mixture the 42,

  22-3-acyl-oxy-21-oxy- nor - allocholenic acid - lactone separates and lets saponifying agents act on this compound.



  The new compound obtained in this way, the 42 @ 22-3,21-dioxy-nor-allo-cholenic acid-lactone, melts at 248-250. It should find therapeutic use or serve as an intermediate product for the preparation of therapeutically ver usable compounds.



       Example: 600 mg of 3,21-diacetoxy-allo-pregnan-20-one from F. 153-154, which corresponds configuratively to cholestanol, are dissolved in 5 cm 'of absolute benzene and mixed with 300 mg of bromoacetic ester and 120 mg of zinc in Reaction brought. It is heated for 2 hours on the water bath, then decomposed with ice and dilute hydrochloric acid and the reaction product is taken up in ether. The ether solution is washed out with water and dilute bicarbonate solution, dried over anhydrous sodium sulfate and evaporated.

   The residue is mixed with 6 g of aluminum oxide and heated to 180 in a sublimation vessel at 0.01 mm pressure until no more distillate is deposited on the cooled condensation vessel. The distillate is adsorbed on aluminum oxide in a benzene solution and broken down into a number of fractions by fractional elution with benzene, ether and acetone. The various fractions are checked in the legal test and those that give a positive color reaction are separated from the others.

   The individual components can be purified by fractional crystallization from ethyl acetate-hexane.



  From the fractions with a positive legal test, the main thing to be obtained is .410,11-3_Acetoxy-21-oxy-nor - allo-cholen-acid-
EMI0002.0001
  
    lacton <SEP> from <SEP> F. <SEP> 193 <SEP> -194, <SEP> the <SEP> by <SEP> acid
<tb> Saponification <SEP> in <SEP> the <SEP> cj211> 22-3,21-D1oS .'- llol'-allo cholenic acid-lactone <SEP> from <SEP> F. <SEP> 248-250 < SEP> is converted to <SEP>.

 

Claims (1)

.PATENTANSPRUCH: Verfahren zur Herstellung eines Lactons der Cy clopentanopolyhy drophenallltllren-Reille, dadurch gekennzeichnet, dass man ein 3,21 Diacyloxy-allo-pregnan-20-on, das konfigura- tiv dem Cholestanol entspricht, mit einem Halogenessigsäureester kondensiert, .PATENT CLAIM: Process for the production of a lactone of the Cyclopentanopolyhy drophenallltllren-Reille, characterized in that a 3.21 diacyloxy-allo-pregnan-20-one, which corresponds configuratively to the cholestanol, is condensed with a haloacetic acid ester aus deal entstandenen Gemisch das J2 2@-3-cvl.os@-- 21-oxy-nol--allo-cholellsäure-lacton abtrennt EMI0002.0014 und <SEP> auf <SEP> diese <SEP> Verbindung <SEP> verseifende <SEP> Mittel <tb> einwirken <SEP> lälit. <tb> Die <SEP> so <SEP> erhaltene <SEP> neue <SEP> Verbindung, <SEP> das <tb> .:1'= >22-3,\?1-Dioxy-nor-allo- <SEP> cholencäure-lacton, <tb> Schmilzt <SEP> bei <SEP> 248-250 . <SEP> Sie <SEP> soll <SEP> therapeu tische <SEP> Vervendung <SEP> finden <SEP> oder <SEP> als <SEP> Zwischen produkt <SEP> zur <SEP> Herstellung <SEP> therapeutisch <SEP> ver wendbarer <SEP> Verbindungen <SEP> dienen. from deal resulting mixture the J2 2@-3-cvl.os @ - 21-oxy-nol - allo-cholellic acid-lactone separates EMI0002.0014 and <SEP> on <SEP> this <SEP> connection <SEP> saponifying <SEP> agent <tb> act <SEP> lälit. <tb> The <SEP> so <SEP> received <SEP> new <SEP> connection, <SEP> that <tb>.: 1 '=> 22-3, \? 1-Dioxy-nor-allo- <SEP> cholenc acid-lactone, <tb> Melts <SEP> at <SEP> 248-250. <SEP> You <SEP> should <SEP> therapeutic <SEP> use <SEP> <SEP> or <SEP> as <SEP> intermediate product <SEP> for <SEP> production <SEP> therapeutic <SEP> ver reversible <SEP> connections <SEP> are used. UNTERANSPRUCH: Verfahren nach Patentanspruch, dadurch gekennzeichnet, datl) man Bromessigester als Halogellessigsälireester verwendet. SUBSTANTIAL CLAIM: Process according to patent claim, characterized in that bromoacetic esters are used as halogenated acetic acid esters.
CH240099D 1938-09-15 1938-09-15 Process for the preparation of a lactone of the cyclopentanopolyhydrophenanthrene series. CH240099A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH240099T 1938-09-15
CH234780T 1938-09-15

Publications (1)

Publication Number Publication Date
CH240099A true CH240099A (en) 1945-11-30

Family

ID=25727936

Family Applications (1)

Application Number Title Priority Date Filing Date
CH240099D CH240099A (en) 1938-09-15 1938-09-15 Process for the preparation of a lactone of the cyclopentanopolyhydrophenanthrene series.

Country Status (1)

Country Link
CH (1) CH240099A (en)

Similar Documents

Publication Publication Date Title
CH240099A (en) Process for the preparation of a lactone of the cyclopentanopolyhydrophenanthrene series.
DE2211214C3 (en)
DE2502690C2 (en) Process for the production of coumarin
DE642290C (en) Process for the representation of reduction products of the male sex hormone and similar substances
AT160572B (en) Process for the preparation of unsaturated oxyketones of the cyclopentanopolydrophenanthrene series or their derivatives.
DE861839C (en) Process for the preparation of threo-1- (4&#39;-nitrophenyl) -2-dichloroacetylamino-1, 3-dichloropropane
DE651612C (en) Process for the preparation of ketodicarboxylic acids and their lactones
DE737571C (en) Process for the preparation of lactones of the cyclopentanopolyhydrophenanthrene series
AT237810B (en) Process for the preparation of 16α-methyl-1,4-pregnadiene-9α-fluoro-11β, 17α, 21-trihydroxy-3,20-dione and its 21-esters
CH242274A (en) Process for the preparation of a lactone of the cyclopentanopolyhydrophenanthrene series.
DE1620031C2 (en) Indolyl (3) alkanecarboxylic acids
DE357663C (en) Process for the preparation of a carboxylic acid of ar-tetrahydro-ª ‰ -naphthol and its ester and acyl derivatives
AT235473B (en) Process for the preparation of 7-dehydro-cholesterol esters
CH240100A (en) Process for the preparation of a lactone of the cyclopentanopolyhydrophenanthrene series.
CH556830A (en) Androstane derivs
CH252485A (en) Process for the production of a bile acid derivative.
CH240101A (en) Process for the preparation of a lactone of the cyclopentanopolyhydrophenanthrene series.
CH246555A (en) Process for the production of a bile acid derivative.
CH242987A (en) Process for the preparation of a lactone of the cyclopentanopolyhydrophenanthrene series.
CH195775A (en) Process for the preparation of a new ester.
CH252484A (en) Process for the production of a bile acid derivative.
CH194450A (en) Process for the preparation of 4,5-androstenediol-3,17.
CH199982A (en) Process for the preparation of a new ester.
CH263974A (en) Process for the separation of octahydrophenanthrene carboxylic acid esters.
CH236759A (en) Process for the preparation of a lactone of the cyclopentanopolyhydrophenanthrene series.